Return to work for patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation

Figures & data

Table 1 Baseline characteristics and HRs (with accompanying 95% CIs) for returning to work within the first year after ASCT for the 164 patients with diffuse large B-cell lymphoma or transformed indolent lymphoma in Denmark in 2000–2012 included in the analysis on return to work

Variables	N (%)	Events	HR (95% CI)	p-value
Total	164	60
Age				0.05
<55 years	86 (52)	13	1.00(ref)
≥55 years	78 (48)	47	1.82(1.0;3.4)
Sex				0.5
Male	104 (63)	38	1.00(ref)
Female	60 (37)	22	0.83(0.5;1.4)
Period				0.6
2000–2003	41 (25)	12	1.00(ref)
2004–2007	66 (40)	42	1.44(0.7;2.9)
2008–2012	57 (35)	22	1.23(0.6;2.5)
Subtype				0.2
DLBCL	86 (52)	26	1.00(ref)
TIL	78 (48)	34	1.39(0.8;2.3)
IPI score at relapse				0.9
Low	50 (31)	17	1.00(ref)
LI/HI/high	61 (37)	21	1.02(0.5;1.9)
Antidepressants or anxiolytics				0.3
No	116 (70)	44	1.00(ref)
Yes	48 (22)	16	0.72(0.4;1.3)
Comorbidities				0.6
None	118 (72)	42	1.00(ref)
One or more	46 (28)	18	1.14(0.7;2.0)
Disposable income				0.2
Low	20 (12)	5	1.00(ref)
Medium	71 (43)	22	1.05(0.4;2.8)
High	73 (45)	33	1.69(0.7;4.3)
Educational level				0.3
Low	43 (26)	19	1.00(ref)
Medium	83 (51)	30	0.79(0.4;1.4)
High	36 (22)	10	0.54(0.3;1.2)
Welfare benefit at the time of relapse				<0.001*
None	63 (38)	38	1.00(ref)
Sick leave	101 (62)	22	0.30(0.2;0.5)
Primary refractory disease				0.05
No	110 (67)	46	1.00(ref)
Yes	54 (33)	14	0.54(0.3;1.00)
Change during salvage treatment				0.2
No	113 (69)	//	1.00(ref)
Yes	19 (12)	//	0.47(0.2;1.5)
Days of admission during salvage				0.05
<14	82 (50)	35	1.00(ref)
14–28	44 (27)	16	0.82(0.5;1.5)
>28	31 (19)	5	0.26(0.1;0.8)
PS at day 7				0.5
0	109 (67)	43	1.00(ref)
>0	40 (24)	9	0.78(0.4;1.6)

Notes:

* p-values significant after Bonferroni adjustment;

// , ≤5 events; Numbers may not add up to 164 due to missing data.

Abbreviations: ASCT, autologous stem cell transplantation; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; HI, high intermediate; HRs, hazard ratios; IPI score, international prognostic index score; LI, low-intermediate; PS, performance status; ref, reference; TIL, transformed indolent lymphoma.

Table 2 Baseline characteristics and HRs (with accompanying 95% 95% CIs) for taking disability pension within the first 2 years after ASCT for the 205 patients with diffuse large B-cell lymphoma or transformed indolent lymphoma in Denmark in 2000–2012 included in the analysis on disability pension^

Variables	N (%)	Events	HR (95% CI)	p-value
Total	205	37
Age				0.6
<55 years	103 (50)	21	1.00 (ref)
≥55 years	102 (50)	16	0.84 (0.4;1.6)
Sex				1.00
Male	130 (63)	23	1.00 (ref)
Female	75 (37)	14	0.99 (0.5;1.9)
Period				0.01
2000–2003	54 (26)	17	1.00 (ref)
2004–2007	80 (39)	13	0.52 (0.3;1.1)
2008–2012	71 (35)	7	0.27 (0.1;0.7)
Subtype				0.8
DLBCL	106 (52)	17	1.00 (ref)
TIL	99 (48)	20	1.02 (0.5;2.0)
IPI score at relapse				0.2
Low	53 (26)	14	1.00 (ref)
LI/HI/high	77 (38)	12	0.61 (0.3;1.3)
Antidepressants or anxiolytics				0.9
No	140 (68)	25	1.00 (ref)
Yes	65 (32)	12	1.03 (0.5;2.0)
Comorbidities				0.01
None	148 (72)	//	1.00 (ref)
One	44 (22)	//	0.46 (0.2;1.3)
Two or more	13 (6)	//	2.80 (1.2;6.8)
Disposable income				0.01
Low	25 (12)	7	1.00 (ref)
Medium	80 (39)	20	0.72 (0.3;1.7)
High	97 (47)	10	0.26 (0.1;0.7)
Educational level				0.5
Low	43 (21)	10	1.00 (ref)
Medium	100 (49)	17	1.01 (0.5;2.3)
High	55 (27)	9	1.59 (0.7;3.9)
Welfare benefit at the time of relapse				<0.001*
None	104 (51)	11	1.00 (ref)
Sick leave	101 (49)	26	3.37 (1.7;6.8)
Primary refractory disease				0.9
Yes	70 (34)	26	1.00 (ref)
No	135 (66)	11	0.96 (0.5;1.9)
Change during salvage				0.1
No	139 (68)	24	1.00 (ref)
Yes	24 (12)	6	2.06 (0.8;5.0)
Days of admission during salvage				0.1
<14	96 (47)	13	1.00 (ref)
14–28	57 (28)	12	1.79 (0.8;3.9)
>28	40 (20)	10	2.48 (1.1;5.7)
PS at day 7				0.02
0	135 (66)	25	1.00 (ref)
>0	47 (23)	12	2.27 (1.1;4.5)	0.02

Notes:

* p-values significant after Bonferroni adjustment;

// , ≤5 events;

^ , numbers may not add up to 205 due to missing data.

Abbreviations: ASCT, autologous stem cell transplantation; CI, confidence interval; DLBCL, diffuse large B-cell lymphoma; HI, high intermediate; HRs, hazard ratios; IPI score, international prognostic index score; LI, low-intermediate; PS, performance status; ref, reference; TIL, transformed indolent lymphoma.

Figure 1 Flowchart of the study population. Patients with diffuse large B-cell lymphoma or transformed indolent lymphoma in Denmark in 2000–2012 included in the analyses on return to work and disability pension.

Abbreviations: ASCT, autologous stem cell transplantation; RTW, return to work.

Figure 2 Cumulative incidence curves for return to work within the first five years following ASCT for the 164 patients with diffuse large B-cell lymphoma or transformed indolent lymphoma in Denmark in 2000–2012 included in the return to work analysis, stratified on age.

Abbreviation: RTW, return to work.